Will 2016 be a landmark year for COPD treatment?

February 03, 2016

London, UK - Dove Medical Press, publisher of International Journal of Chronic Obstructive Pulmonary Disease (IJCOPD), today announced the launch of Open Outlook: COPD, a year-long exploration of the horizon of COPD treatment. The program forms part of their 10th anniversary commemorations.

The program will take an in in-depth look at the impact of advances on COPD management and outline what this means for future research. Contributors will include IJCOPD Editor-in-Chief Dr Richard Russell, Lymington New Forest Hospital and University of Oxford, UK, Associate Editor, Professor David Mannino, University of Kentucky, USA and Professor Peter Barnes, Imperial College London, UK.

"The starting point for this program is to look at what the last 10 years have meant for our existing management of COPD. We'll then look at what's ahead in the next five, including COPD treatment guidelines, preclinical and clinical targets and the possibilities presented by Big Data," explained Dr Russell. "We expect significant advances in 2016, and we'll outline what that means for patient care."

The program will consist of a series of concise video perspectives, published sequentially on the IJCOPD journal webpage. The first video will be available from February 2016 at http://www.dovepress.com/ijcopdoo.t
-end-
About Dove Medical Press

Dove Medical Press Ltd is a privately held UK company specializing in the publication of Open Access peer-reviewed journals across the broad spectrum of science, technology and especially medicine. Dove Medical Press was founded with the objective of combining the highest editorial standards with the 'best of breed' new publishing technologies. Dove Medical Press launched their first journals in 2005.

Dove Medical Press is a member of OASPA, ALPSP, DOAJ, the Publisher's Association, HINARI and COPE.

About the International Journal of Chronic Obstructive Pulmonary Disorder (IJCOPD)

Launched in 2006, IJCOPD (Impact Factor: 3.141) is an international, peer-reviewed Open Access journal of therapeutics and pharmacology focusing on concise rapid reporting of clinical studies and reviews in COPD. Directed at specialists and healthcare professionals. special focus is given to the pathophysiological processes underlying the disease, intervention programs, patient focused education, and self management protocols.

Dove Medical Press

Related COPD Articles from Brightsurf:

Promising therapeutic approach against COPD
Chronic obstructive pulmonary disease (COPD) is one of the most common and deadliest diseases worldwide.

COPD underdiagnosed in older adults, but can be managed
''Recognizing and Treating COPD in Older Adults'' the latest issue of the What's Hot newsletter from The Gerontological Society of America, addresses what is known about the prevalence, incidence, and impact of chronic obstructive pulmonary disease (COPD) in older adults.

Undersized airways may explain why nonsmokers get COPD
A mismatch between airway and lung size may explain why some nonsmokers get COPD and some heavy smokers do not, according to a new study from Columbia University Irving Medical Center.

Is pulmonary rehab after hospitalization for COPD associated with better survival?
Claims data for nearly 200,000 Medicare patients were used to examine the association between starting pulmonary rehabilitation within 90 days of being hospitalized for chronic obstructive pulmonary disease (COPD) and survival after one year.

COPD and smoking associated with higher COVID-19 mortality
Current smokers and people with chronic obstructive pulmonary disease (COPD) have an increased risk of severe complications and higher mortality with COVID-19 infection, according to a new study published May 11, 2020 in the open-access journal PLOS ONE by Jaber Alqahtani of University College London, UK, and colleagues.

COPD as a lung stem cell disease
Two internationally renowned stem cell researchers at the University of Houston have found an abundance of abnormal stem cells in the lungs of patients who suffer from Chronic Obstructive Pulmonary Disease (COPD), a leading cause of death worldwide.

New hope for COPD patients possible with in-home device
In a new paper published Feb. 4 in JAMA, Mayo Clinic researchers describe the benefits of in-home noninvasive ventilation therapy, which includes a type referred to as bilevel positive airway pressure, or BiPAP -- for many patients with chronic obstructive pulmonary disease (COPD).

COPD appears to cause more severe symptoms in women
Women who develop COPD report smoking fewer cigarettes than men; and yet, women experience greater breathing impairments, are subjected to more acute exacerbations of symptoms and report lower quality of life than men with the disease, according to research presented at ATS 2019.

African-Americans with COPD appear less likely to use pulmonary rehab
African-American patients with chronic obstructive pulmonary disease, or COPD, are less likely to participate in pulmonary rehabilitation programs than white patients, even when there are programs nearby.

COPD and type 2 diabetes
COPD and type 2 diabetes are two highly prevalent global health conditions associated with high mortality and morbidity.

Read More: COPD News and COPD Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.